Cinclus Pharma
34.2 SEK +8.57%Be the first to follow this company
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CINPHA
Daily low / high price
31.2 / 34.5
SEK
Market cap
1.59B SEK
Turnover
25.39M SEK
Volume
766K
Latest videos
Financial calendar
Interim report
2024-08-29
Interim report
2024-11-14
Annual report
2025-02-20
Interim report
2025-05-20
General meeting
2025-05-22
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Peter Unge | 7.7 % | 7.7 % |
Kjell Andersson | 7.3 % | 7.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Meddelande om stabiliseringsåtgärder
Stabilization notice
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Antal aktier och röster i Cinclus Pharma
Number of shares and votes in Cinclus Pharma
![Cinclus Pharma, IPO](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/a5aff063-e6d3-42d8-803c-76fa93051463.png)